For constitutional studies, a full cytogenetics karyotype is prepared from cultured cells and any abnormalities are confirmed with appropriate FISH probes to clarify the findings and interpretation.  FISH probes for specific syndromes based on the patient phenotype may be ordered.  Targeted FISH for family members of known deletion or duplication carriers is also available. 

Showing Results 1 to 10 of 18.

12 Centromere FISH

View Test

8 Centromere FISH

View Test

AneuVysion FISH

  • Test Code:
    7018
  • Department:
  • Test Synonyms:
    Prenatal FISH Aneuploidy Screen I-FISH
View Test

Angelman Syndrome (SNRPN/D15S10) FISH

  • Test Code:
    7020
  • Department:
  • Test Synonyms:
    del(15)(q11.2-q13) Prader-Willi syndrome
View Test

CEP X and CEP Y FISH

View Test

Cri-du-Chat (5p-) FISH

  • Test Code:
    8105
  • Department:
  • Test Synonyms:
    Cat cry syndrome 5p- del(5)(p15.2)
View Test

DiGeorge Syndrome (TUPLE1) FISH

  • Test Code:
    7140
  • Department:
  • Test Synonyms:
    Velocardiofacial syndrome VCFS DGS Deletion 22q11.2 syndrome
View Test

FISH Library - Constitutional

  • Test Code:
    7300
  • Department:
  • Test Synonyms:
    AneuVysion (chromosomes 13, 18, 21, X and Y) Angelman Syndrome (SNRPN/D15S10) (15q11-13) CEP X and CEP Y Cri-du-chat (5p-) Syndrome (5p15.2) DiGeorge Syndrome (DGS) (TUPLE1) (22q11.2) Kallman Syndrome (KAL) (Xp22.3) Miller-Dieker Syndrome (LIS1) (17p13.3) Prader-Willi Syndrome (SNRPN/D15S10) (15q11-13) SHOX-related haploinsufficiency disorders (SHOX) (Xp22.33) Smith-Magenis Syndrome (SMS) (17p11.2) SNRPN Dup(15) in autism SRY-related disorders of sex development (SRY) (Yp11.3) Steroid Sulfatase (STS) (Xp22.3) Velocardiofacial Syndrome (VCFS) (TUPLE1) (22q11.2) Williams Syndrome (ELN) (7q11.23) Wolf-Hirshhorn (4p-) Syndrome (WHS) (4p16.3)
View Test

Miller-Dieker FISH

View Test

Prader-Willi Syndrome (SNRPN/D15S10) FISH

View Test

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More